why choose us

First received: October 23, 2023

Clinical Trial: Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Penile Squamous Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: Phase II Study of Enfortumab Vedotin Treatment for Metastatic Squamous Cell Carcinoma of the Penis

Brief Summary: This phase II trial tests how well enfortumab vedotin works for treating patients with squamous cell carcinoma of the penis that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable).Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin.It works by helping the immune system to slow or stop the growth of tumor cells.Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill…

Read more